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ORIGINAL ARTICLE
Global molecular epidemiology and genetic diversity of
Fusarium, a signiﬁcant emerging group of human
opportunists from 1958 to 2015
Abdullah MS Al-Hatmi1,2,3, Ferry Hagen4, Steph BJ Menken2, Jacques F Meis4,5 and G Sybren de Hoog1,2,6,7
Fusarium is a rapidly emerging, multidrug-resistant genus of fungal opportunists that was ﬁrst identiﬁed in 1958 and is
presently recognized in numerous cases of fusariosis each year. The authors examined trends in global Fusarium distribution,
clinical presentation and prevalence since 1958 with the assumption that their distributions in each region had remained
unaltered. The phylogeny and epidemiology of 127 geographically diverse isolates, representing 26 Fusarium species, were
evaluated using partial sequences of the RPB2 and TEF1 genes, and compared with AFLP ﬁngerprinting data. The molecular
data of the Fusarium species were compared with archived data, which enabled the interpretation of hundreds of cases
published in the literature. Our ﬁndings indicate that fusariosis is globally distributed with a focus in (sub)tropical areas.
Considerable species diversity has been observed; genotypic features did not reveal any clustering with either the clinical data or
environmental origins. This study suggests that infections with Fusarium species might be truly opportunistic. The three most
common species are F. falciforme and F. keratoplasticum (members of F. solani species complex), followed by F. oxysporum
(F. oxysporum species complex).
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INTRODUCTION
Fusarium infections are a major challenge with respect to the diagnosis
and treatment, especially in neutropenic patients. Disseminated
infections may be fatal and are a considerable source of increased
healthcare costs. A major area of concern is the intrinsic resistance to a
broad range of antifungals,1 which is a characteristic of Fusarium.
During the past decade, the F. solani complex has received special
interest because of the increasing numbers of infections worldwide.2
More than 300 cases of Fusarium keratitis were associated with
contaminated contact lens cleaning solution, causing outbreaks
between 2005 and 2007, where members of the F. solani species
complex played a major role.3 Furthermore, reservoirs of infectious
Fusarium species in hospital environments, especially plumbing and
water systems, have been reported.4
Although human fusariosis was only recognized since the late 1950s
and endemic areas are mostly located in tropical and subtropical
countries,5 their global signiﬁcance has only recently come into focus
within the past three decades. Etiological agents differ in antifungal
susceptibility,6 virulence proﬁles, geographic distribution, ecological
niches, life cycle, host and mycotoxin production.7 Although agents of
fusariosis are mostly environmental,8 the potential of nosocomial
transmission has recently been raised,9 especially with reference to the
high mortality rate of ~ 90% in patients with prolonged and severe
neutropenia.10
The burden of disease has not been established, but numerous
clinical case series and case reports provide an estimate of the
magnitude of the problem. Most published studies have focused on
prevalence in single healthcare centers.10–16 Nucci et al.17 reported 233
cases from different hospitals on a global scale. Mohammed et al.18
reported 26 cases from the United States and reviewed 97 cases from
the literature, and Horn et al.12 described 65 cases from the North
American Path Alliance Registry. A major problem in comparative
studies is the subdivision of the classical species into a series of
molecular siblings, which renders the older literature without sequence
data uninterpretable. Despite the current clinical importance of the
organism, the phylogenetic relationships among species, varieties and
geographical groups in Fusarium are currently elusive. Hence, the re-
interpretation of these data in the light of modern molecular
phylogeny is compulsory.
Molecular phylogenetic studies have led to the description of many
Fusarium species with clinical relevance. These include members of
the F. solani species complex, namely, F. falciforme, F. keratoplasticum,
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F. lichenicola, F. petroliphilum, F. pseudensiforme and F. solani (FSSC5),
which is also known as Fusisporium solani and Fusarium haplotype ‘6’.
The F. oxysporum species complex (FOSC) contains three lineages,
which are involved in fusariosis and still have not been formally
introduced as taxonomic species. The F. fujikuroi species complex
includes F. acutatum, F. ananatum, F. anthophilum, F. andiyazi,
F. fujikuroi s.s., F. globosum, F. guttiforme, F. musae, F. napiforme,
F. nygamai, F. verticillioides, F. proliferatum, F. ramigenum, F. sacchari,
F. subglutinans, F. temperatum and F. thapsinum. Although rare,
species of other Fusarium lineages are emerging as potential oppor-
tunistic pathogens, for example, in the F. incarnatum-equiseti species
complex (FIESC; F. incarnatum and F. equiseti), the F. dimerum
species complex (F. dimerum, F. delphiniodes and F. penzigii), the
F. chlamydosporum species complex, the F. sambucinum species
complex (F. armeniacum, F. brachygibbosum, F. langsethiae and
F. sporotrichioides) and the F. tricictum species complex (F. acuminatum
and F. ﬂocciferum).1
Over the past decade, the number of cases of fusariosis has
increased worldwide, but there are only a few reports describing the
molecular epidemiology; therefore, the aim of the present study is to
introduce a hypothetical system that permits the interpretation and
use of at least a part of the literature where sequence data are lacking.
Pre-molecular publications, which include interpretable case reports
and geographical information, were collected. Subsequently, available
Fusarium strains that were collected worldwide and deposited during
the past century in the CBS-KNAW, Fungal Biodiversity Centre,
culture collection Utrecht, The Netherlands, were sequenced and re-
identiﬁed with current diagnostic technology, which enables the
phylogenetic analysis of the human–pathogenic Fusarium species.
These data were then compared with published materials and their
distribution with the assumption that their distributions in each region
had remained unaltered.
MATERIALS AND METHODS
Fungal strains
A total of 127 strains collected from clinical samples (n= 74; 58.3%;
collected between 1978 and 2015) and strains collected from the
environment (n= 53; 41.7%; collected between 1929 and 2015) were
analyzed. All of the strains were maintained under the name
‘Fusarium’ in the reference collection of CBS-KNAW, Utrecht, the
Netherlands. The data regarding geographic origins and sources of
isolation are listed in Table 1. All of the available type strains were
included. Stock cultures were maintained on slants of 2% malt extract
agar at 24 °C. The strains were assigned to a clinical subgroup and an
environment subgroup.
DNA extraction
DNA was extracted following the Quick Cetyl trimethylammonium
bromide (CTAB) protocol. A total of 1–10 mm3 fungal material was
transferred to 2- mL screw-capped tubes preﬁlled with 490 μL 2×
CTAB buffer and 6–10 acid-washed glass beads. A total of 10 μL of
proteinase K was added and mixed thoroughly on a MoBio vortex
(MO BIO Laboratories, Inc., Carlsbad, CA, USA) for 10 min. Then,
500 μL of chloroform:isoamylalcohol (24:1) was added and shaken for
2 min after incubation for 60 min at 60 °C. The tubes were centrifuged
for 10 min at 14 000 rpm, and the supernatant was collected in a new
Eppendorf tube. To ~ 400 μL of the DNA sample, 2/3 vol (~270 μL) of
ice-cold isopropanol was added and centrifuged again at 14 000 rpm
for 10 min, and the upper layer was dissolved in 1 mL ice-cold 70%
ethanol. The tubes were centrifuged again at 14 000 rpm for 2 min,
air-dried and resuspended in 50 μL TE buffer. The quality of the
genomic DNA was veriﬁed by running 2–3 μL on a 0.8% agarose gel.
Then, the DNA was quantiﬁed with a NanoDrop 2000 spectro-
photometer (Thermo Fisher, Wilmington, DE, USA), and the samples
were stored at − 20 °C until ready for analysis.
DNA ampliﬁcation and sequencing
The following two gene regions were ampliﬁed directly from the
genomic DNA: the second largest subunit of RNA polymerase (RPB2;
Reeb et al.19) and the translation elongation factor-1α (TEF1α;
O'Donnell et al.20) were ampliﬁed and sequenced following the
methods published by Saleh et al.16 The PCR reactions were
performed in a volume of 12.5 μL containing 1.25 μL of 10× PCR
buffer, 7.5 μL of water, 0.5 μL of dNTP mix (2.5 mM), 0.25 μL of each
primer (10 pmol), 0.05 μL of Taq polymerase (5 U/μL), 0.7 μL of
dimethylsulphoxide and 1 μL of template DNA (100 ng/μL). The
ampliﬁcation was performed with the ABI Prism 2720 thermal cycler
(Applied Biosystems, Foster City, CA, USA). The cycling conditions
included 1 cycle of 5 min at 94 °C, 10 cycles of 45 s at 94 °C, 45 s at
55 °C and 1.5 min at 72 °C, 30 cycles of 45 s at 94 °C, 45 s at 52 °C and
1.30 min at 72 °C, a post elongation step of 6 min at 72 °C for TEF1
(EF1, EF2) and a pre-denaturation for 3 min at 95 °C, 5 cycles of 45 s
at 95 °C, 45 s at 58 °C and 2 min at 72 °C, 5 cycles of 45 s at 95 °C, 45 s
at 56 °C and 2 min at 72 °C, 30 cycles of 45 s at 95 °C, 45 s at 52 °C
and 2 min at 72 °C, and a post elongation step of 8 min at 72 °C for
RPB2 (5F2 and 7cr). The PCR products were visualized by electro-
phoresis on 1% (w/v) agarose gels. The sequencing PCR was
performed as follows: 1 min at 95 °C followed by 30 cycles consisting
of 10 s at 95 °C, 5 s at 50 °C and 2 min 60 °C. The reactions were
puriﬁed with Sephadex G-50 ﬁne (GE Healthcare Bio-Sciences,
Uppsala, Sweden), and the sequencing was conducted on an ABI
3730xL automatic sequencer (Applied Biosystems) with a BigDye v3.1
terminator cycle sequencing kit (Applied Biosystems).
Identiﬁcation
The strains were identiﬁed by BLAST in GenBank, Fusarium MLST
(http://www.cbs.knaw.nl/fusarium/)20 and the FUSARIUM-ID (http://
isolate.fusariumdb.org/)21 databases. In addition, the phylogenetic
placements with species/haplotypes within species complexes were
veriﬁed with available databases that are speciﬁc for Fusarium.
Phylogenetic analyses
Sequences of TEF1 and RPB2 were undertaken to extend the genetic
characterization of 127 isolates of Fusarium species previously
characterized in terms of morphological characteristics. The sequences
were edited using SeqMan in the Lasergene package (DNAstar,
Madison, WI, USA). A phylogenetic approach was used to investigate
the relationship between 65 strains of Fusarium species including type
and reference strains. The sequences were aligned using MAFFT
v. 7.127 (http://mafft.cbrc.jp) followed by manual adjustments with
MEGA v. 6.2.22 A combined alignment was constructed for RPB2 and
TEF1 for both the reference and test strains. The best-ﬁt model of
evolution was determined by MEGA v. 6.2.22 A bootstrapped
maximum-likelihood analysis was performed using RAxMLVI-HPC
v. 7.0.323 as implemented on the Cipres portal (http://www.phylo.org/),24
with non-parametric bootstrapping using 1000 replicates. Detailed
analyses of medically important strains were compared in relation with
their clinical cases. For instance, F. solani actually represents a complex
(that is, the F. solani species complex).
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Table 1 Isolates of Fusarium included in this study that were used for the sequence analysis and ampliﬁed fragment length polymorphism
analysis, except for six RPB2 and TEF1, which were retrieved from GenBank
CBS number Species name Country Source GenBank accession number
TEF1 RPB2
CBS 130548 F. acutatum Iran Onychomycosis (Human) KR071756 KU604289
CBS 113964 F. acutatum Egypt Environmental KR071759 KU604290
CBS 739.97 F. acutatum India Environmental KR071757 KU604288
CBS 401.97 F. acutatum India Environmental KR071755 KU604287
CBS 402.97 F. acutatum India Environmental KR071754 KT154005
CBS 118517 F. ananatum South Africa Environmental KR071761 KU604273
CBS 118518 F. ananatum South Africa Environmental KU711690 KU604271
CBS 118516 F. ananatum South Africa Environmental KR071760 KU604269
CBS 184.29 F. ananatum Unknown Environmental KR071762 KU604272
CBS 256.93 F. andiyazi Cuba Environmental KR071719 KU604231
CBS 119857 F. andiyazi South Africa Environmental KP662901 KT154004
CBS 737.97 F. anthophilum Germany Environmental KU711685 KU604277
CBS 222.76 F. anthophilum Germany Environmental KR071766 KT154006
CBS 119858 F. anthophilum USA Environmental KR071764 KU604275
CBS 119859 F. anthophilum New Zealand Environmental KR071765 KU604279
CBS 961.87 F. concolor South Africa Environmental KR071773 KU604556
CBS 676.94 F. concolor South Africa Environmental KR071774 KU604237
CBS 111770 F. concolor Spain Keratitis (Human) KU711719 KU604323
C26 F. delphinoides India Keratitis (Human) KU711775 KU604380
C52 F. dimerum India Keratitis (Human) KU711776 KU604381
CBS 135550 F. equiseti Mexico Keratitis (Human) KU711721 KU604324
CBS 135552 F. equiseti Mexico Keratitis (Human) KU711723 KU604325
CBS 135553 F. equiseti Mexico Keratitis (Human) KU711722 KU604326
CBS 135532 F. falciforme Mexico Keratitis (Human) KU711737 KU604356
CBS 135533 F. falciforme Mexico Keratitis (Human) KU711738 KU604362
CBS 135521 F. falciforme Mexico Keratitis (Human) KU711733 KU604357
CBS 135520 F. falciforme Mexico Keratitis (Human) KU711732 KU604363
CBS 135526 F. falciforme Mexico Keratitis (Human) KU711734 KU604366
CBS 135524 F. falciforme Mexico Keratitis (Human) KU711730 KU604358
CBS 135525 F. falciforme Mexico Keratitis (Human) KU711731 KU604359
CBS 135558 F. falciforme Mexico Keratitis (Human) KU711736 KU604368
CBS 135559 F. falciforme Mexico Keratitis (Human) KU711735 KU604369
CBS 135513 F. falciforme Mexico Onychomycosis (Human) KU711724 KU604360
CBS 135512 F. falciforme Mexico Onychomycosis (Human) KM401894 KM401892
C256 F. falciforme India Keratitis (Human) KU711725 KU604361
CBS 135522 F. falciforme Mexico Keratitis (Human) KU711726 KU604364
CBS 135523 F. falciforme Mexico Keratitis (Human) KU711727 KU604367
CBS 125177 F. ﬁcicrescens Iran Environmental KP662898 KT154001
CBS 125178 F. ﬁcicrescens Iran Environmental KP662899 KT154002
CBS 125181 F. ﬁcicrescens Iran Environmental KP662900 KT154003
CBS 449.95 F. fujikuroi France Environmental KR071742 KU604259
CBS 257.52 F. fujikuroi Japan Environmental KU711678 KU604257
CBS 262.54 F. fujikuroi India Environmental KR071744 KU604256
CBS 221.76 F. fujikuroi Taiwan Environmental KR071741 KU604255
CBS 130402 F. fujikuroi USA Human skin (Human) KU711677 KU604261
CBS 121864 F. fujikuroi USA Environmental KR071743 KU604258
CBS 119855 F. fujikuroi USA Environmental KU711679 KU604260
CBS 454.97 Fusarium sp Sudan Environmental KU711697 KU604266
CBS 483.94 Fusarium sp Australia Environmental KU711698 KU604267
CBS 119850 Fusarium sp Australia Environmental KU711699 KU604268
CBS 135528 F. keratoplasticum Mexico Keratitis (Human) KU711743 KU604338
dH22044/F610 F. keratoplasticum Netherlands Keratitis (Human) KU711744 KU604339
CBS 135527 F. keratoplasticum Mexico Keratitis (Human) KU711742 KU604340
CBS 135531 F. keratoplasticum Mexico Eumycetoma (Human) KU711741 KU604353
CBS 135530 F. keratoplasticum Mexico Eumycetoma (Human) KU711740 KU604352
CBS 135529 F. keratoplasticum Mexico Keratitis (Human) KU711739 KU604354
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Table 1 (Continued )
CBS number Species name Country Source GenBank accession number
TEF1 RPB2
dH21918/F605 F. keratoplasticum Netherlands Nail infection (Human) KU711746 KU604344
dH22043/F609 F. keratoplasticum Netherlands Foot infection (Human) KU711747 KU604341
CBS 748.97 F. napiforme Namibia Environmental KR071712 KU604233
CBS 674.94 F. napiforme Australia Environmental KR071713 KU604239
CBS 135139 F. napiforme India Keratitis (Human) KR071717 KU604234
CBS 135140 F. napiforme India Keratitis (Human) KR071714 KU604235
dH 21772/F602 F. oxysporum Netherlands Nail infection (Human) KU711714 KU604318
dH22047/F611 F. oxysporum Netherlands Nail infection (Human) KU711711 KU604314
CBS 135560 F. oxysporum Mexico Keratitis (Human) KU711709 KU604317
CBS 135561 F. oxysporum Mexico Keratitis (Human) KU711710 KU604316
CBS 463.91 F. oxysporum Germany Nail infections (Human) KU711712 KU604315
CBS 135515 F. petroliphilum Mexico Keratitis (Human) KU711760 KU604336
CBS 135518 F. petroliphilum Mexico Keratitis (Human) KU711762 KU604334
CBS 135519 F. petroliphilum Mexico Keratitis (Human) KU711765 KU604331
CBS 135535 F. petroliphilum Mexico Keratitis (Human) KU711761 KU604335
CBS 135514 F. petroliphilum Mexico Mycotic keratitis (Human) KU711767 KU604330
CBS 187.34 F. phyllophilum UK Environmental KU711680 KU604300
CBS 246.61 F. phyllophilum Germany Environmental KU711681 KU604301
CBS 480.77 F. proliferatum Netherlands Environmental KR071736 KU604245
CBS 182.32 F. proliferatum USA Environmental KR071734 KU604246
CBS 183.29 F. proliferatum Japan Environmental KR071735 KU604242
CBS 184.33 F. proliferatum Guyana Environmental KR071737 KU604244
CBS 125014 F. proliferatum USA Deep infection (Human) KR071738 KU604243
CBS 131391 F. proliferatum Australia Environmental KR071732 KU604247
CBS 133030 F. proliferatum Iran Onycomycosis (Human) KR071733 KU604248
CBS 135547 F. proliferatum Mexico Keratitis (Human) KU711675 KU604254
CBS 135549 F. proliferatum Mexico Keratitis (Human) KU711676 KU604253
CBS 116324 F. proliferatum Spain Keratitis (Human) KR071731 KU604249
CBS 130179 F. proliferatum USA Deep infection (Human) KR071739 KU604241
dH23807/CBS 132761 F. proliferatum France Deep infection (Human) KU711673 KU604250
dH23808/CBS 132762 F. proliferatum France Deep infection (Human) KU711674 KU604252
dH23810/CBS 132764 F. proliferatum Unknown Environmental KU711672 KU604251
CBS 135554 F. pseudensiforme Mexico Eumycetoma (Human) KU711769 KU604377
CBS 135555 F. pseudensiforme Mexico Eumycetoma (Human) KU711770 KU604375
CBS 135557 F. pseudensiforme Mexico Keratitis (Human) KU711771 KU604376
CBS 135142 F. sacchari India Corneal ulcer (Human) KR071749 KU604304
CBS 135143 F. sacchari India Corneal ulcer (Human) KR071748 KU604307
CBS 135144 F. sacchari India Corneal ulcer (Human) KR071750 KU604305
CBS 135145 F. sacchari India Corneal ulcer (Human) KR071751 KU604306
CBS 223.76 F. sacchari India Environmental KU711669 KU604309
CBS 134.73 F. sacchari Guyana Environmental KR071753 KU604303
CBS 131369 F. sacchari Australia Environmental KR071752 KU604302
CBS 121683 F. sacchari India Endophthalmitis (Human) KR071747 KU604308
CBS 135563 F. solani (FSSC5) Mexico Hyalohyphomycosis (Human) KU711758 KU604372
CBS 135564 F. solani (FSSC5) Mexico Hyalohyphomycosis (Human) KU711759 KU604373
CBS 135565 F. solani (FSSC5) Mexico Hyalohyphomycosis KU711757 KU604371
CBS 119831 F. subglutinans New Guinea Environmental KR071769 KU604281
CBS 747.97 F. subglutinans USA Environmental KU711691 KU604280
CBS 135538 F. temperatum Mexico Pulmonary infection (Human) KF956082 KU604283
CBS 135539 F. temperatum Mexico Pulmonary infection (Human) KF956083 KU604286
CBS 135540 F. temperatum Mexico Keratitis (Human) KF956084 KU604285
CBS 135541 F. temperatum Mexico Keratitis (Human) KF956085 KU604284
CBS 776.96 F. thapsinum USA Environmental KR071726 KU604294
CBS 733.97 F. thapsinum South Africa Environmental KR071730 KU604299
CBS 130176 F. thapsinum Italy Human mycetoma (Human) KR071727 KU604298
CBS 119833 F. thapsinum USA Environmental KU711717 KU604297
CBS 109077 F. thapsinum Ethiopia Environmental KR071728 KU604295
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AFLP
The Fusarium strains were subjected to ampliﬁed fragment length
polymorphism (AFLP) genotyping using a previously described
method.25 However, for the ampliﬁcation of the DNA fragments,
the selective residues (underlined) of the HpyCH4IV-primer (5′-GAT
GAG TCC TGA CTA ATG AG-3′) and MseI-primer (5′-Flu-GTA
GAC TGC GTA CCC GTAC-3′; MseI-C-selective primer) were
replaced. The amplicons were diluted 20× with double-distilled
H2O (ddH2O); 1 μL of the diluted amplicon was then added to a
mixture of 8.9 μL ddH2O and 0.1 μL LIZ600 (Applied Biosystems)
followed by a heating step for 1 min at 100 °C and cooling to 4 °C. The
AFLP fragment analysis was conducted using an ABI3500xL Genetic
Analyzer (Applied Biosystems) according to the manufacturer’s
instructions. The raw data were then inspected visually after importa-
tion into BioNumerics v7.5 (Applied Maths, Sint Martens-Latem,
Belgium) and analyzed by an Unweighted Pair Group Method with
Arithmetic Mean clustering using the Pearson correlation coefﬁcient.
The analysis was restricted to DNA fragments in the range of
40–400 bp. The ﬁnal AFLP dendrograms were based on the combina-
tion of sequencing and the AFLP data of both dendrograms.
Meta-analysis
The authors analyzed the existing medical literature on human cases of
fusariosis from 1958 until December 2015. The authors conducted a
systematic literature search using PubMed, and the terms ‘Fusarium’
and ‘fusariosis’ were used for the search and both were also used as
MeSH words and free words. Studies were only included that reported
data for the individual cases because data provided in aggregate often
lacked speciﬁc information for individual cases. Only cases with either
histologically or culturally proven Fusarium infection were included. A
total of 388 case reports in ~ 265 published studies were collected on a
worldwide basis. The numbers are approximate because some cases
have been used in repeated publications. Only cases with either
histologically or culturally proven Fusarium infection were included
(Supplementary Reference S1).
RESULTS
Types of articles
A total of 388 cases of fusariosis from 1958 until December 2015 were
used in the literature data analysis. This included articles that were
mostly single case reports, two patient cases and a series of cases of
fusariosis. The reported cases of fusariosis were identiﬁed from all over
the world, and particularly from tropical and subtropical countries
with a large agrarian population such as Brazil, China, Colombia,
India and Mexico. The other areas with frequent fusariosis were
Australia, South Africa, Turkey and the Americas. Fusarium infections
have also been reported from different countries in eastern and
western Europe.
Patient characteristics. An overview of the cases of fusariosis pub-
lished in the medical literature, which includes the great majority of
cases published to date, is provided in Table 2. The majority of
patients were male (n= 253; 65.2%; mean 41 years; range
three months–83 years). Over a third of the patients (n= 143;
36.9%) had various underlying conditions at the time when the
Fusarium infection was diagnosed. Causes of immunosuppression
were hematological diseases and hematologic malignancies (n= 122;
31.4%) and cancer of the solid organs (n= 17; 4.8%). Other causes of
immunosuppression were medication (n= 140; 36%), which included
antibiotic (n= 34; 8.8%) and steroid treatment (n= 10; 2.6%).
Pathogen introduction was ranked as trauma (n= 18; 4.6%), indwel-
ling catheters (n= 2; 0.5%), nasogastric tubes (n= 2; 0.5%) and
dialysis (n= 3; 0.77%). No metabolic disorders, such as diabetes, were
recorded in association with infection.
Type of infections
Infections due to Fusarium were predominantly found to be superﬁcial
and subcutaneous (n= 174; 44.8%), occurring on the skin (n= 62;
16%), eyes (n= 66; 17%) and nails (n= 25; 6.4%). Deep infections
involved bone, joint and lung (n= 4; 1%), heart (n= 3; 0.77%), and
peritoneum (n= 2; 0.5%). The sum of the invasive and disseminated
cases was n= 109 (28%), some of which were associated with
fungemia (n= 25; 6.4%) or disseminated disease with brain abscesses
(n= 4; 1%; Table 2).
Treatment
An overview of the reported treatment of the cases of fusariosis is
shown in Table 3. The most widely used antifungal agent was
amphotericin B deoxycholate (n= 198; 51%), followed by liposomal
amphotericin B (n= 45; 11.6%), voriconazole (n= 42; 10.8%),
Table 1 (Continued )
CBS number Species name Country Source GenBank accession number
TEF1 RPB2
CBS 114579 F. verticillioides Austria Sputum (Human) KU711696 KU604220
CBS 115135 F. verticillioides Sweden Deep infection (Human) KR071710 KU604217
CBS 131390 F. verticillioides Australia Environmental KR071711 KU604225
CBS 116665 F. verticillioides Unknown Environmental KR071705 KU604221
CBS 135542 F. verticillioides Mexico Onychomycosis (Human) KU711693 KU604227
CBS 135543 F. verticillioides Mexico Onychomycosis (Human) KU711694 KU604228
CBS 135545 F. verticillioides Mexico Onychomycosis (Human) KX584417 KU604229
CBS 576.78 F. verticillioides Russia Environmental KR071703 KU604216
CBS 579.78 F. verticillioides USA Ulcer of left leg (Human) KR071706 KU604223
CBS 122159 F. verticillioides Spain Environmental KR071707 KU604224
CBS 123670 F. verticillioides USA Environmental KR071708 KU604222
CBS 102699 F. verticillioides Germany Abdominal drainage (Human) KR071704 KU604218
CBS 108922 F. verticillioides Germany Urine (Human) KR071709 KU604219
CBS 131389 F. verticillioides Australia Environmental KU711695 KU604226
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5-ﬂucytosine (n= 30; 7.7%), itraconazole (n= 26; 6.7%), ﬂuconazole
(n= 25; 6.4%) and ketoconazole (n= 19; 4.9%).
The antifungal combinations used in treating fusariosis were given
either as a two- or a three-drug combination. The most frequently
used combination of two drugs was amphotericin B with voriconazole
(n= 24; 6%), followed by amphotericin B with 5-ﬂucytosine (n= 20;
5%), amphotericin B with ketoconazole (n= 4; 1%) and amphotericin
B with ﬂuconazole (n= 4; 1%). Other combinations were used in one
or two cases. Triple combinations were used in 14 cases (n= 14;
3.6%). In addition, surgery with antifungal treatment was used in 80
cases (20.6%). In addition to antifungal therapy and surgery,
granulocyte transfusions or granulocyte–colony-stimulating factor
transfusions were also used. Only seven isolates were associated with
cases where no treatment was reported (Table 3). It was not possible
to look at the changes in treatment over time, although the authors
assume that azole treatments have increased while AmB has declined.
With the current guidelines, liposomal amphotericin B (n= 45;
11.6%) and voriconazole (n= 42; 10.8%) are very similar according
to the data from the reported cases.
Genetic analysis
A total of 127 Fusarium strains deposited in the CBS-KNAW
collection were partially sequenced for RPB2 and TEF1. The resulting
two phylogenies yielded almost identical topologies with similar
Table 2 Characteristics of 388 patients with fusariosis and literature
cases from 1958 until 2015
Characteristic Number of patients
Total 388
Age, years (range) 3 months−82 years
Sex, M:F:unknown 253 (65.3%):
125 (32.2%):
10 (2.5%)
Underlying condition
Transplantation
Liver 5 (1.2%)
Lung 4 (1%)
Bone morrow 29 (7.5%)
Multivisceral (stomach, duodenum, pancreas and
intestine)
1 (0.25%)
7 (1.8%)
Kidney 3 (0.77%)
Heart 4 (1%)
Stem cells 38 (9.8%)
Trauma/burns 27 (7%)
Foreign body 18 (4.6%)
Contact lens 4 (1%)
Catheter 2 (0.5%)
Graft 3 (0.77%)
Nasogastric tube 3 (0.77%)
Dialysis 4 (1%)
Cancer
Hematologic 122 (31.4%)
Solid organ 17 (4.8%)
Medication
Antibiotics 140 (36%)
Steroids 34 (8.8%)
No 20 (5%)
Site of infection
Superﬁcial
Skin 62 (16%)
Eye 66 (17%)
Nail 25 (6.44)
Bone 4 (1%)
Joint 4 (1%)
Lung 4 (1%)
Endocarditis 3 (0.77%)
Peritoneum 2 (0.5%)
Perinephric abscess 2 (0.5%)
Disseminated 109 (28%)
Blood 25 (6.4%)
Brain 4 (1%)
Abbreviations: female, F; male, M.
Table 3 Treatment administered to 388 patients with fusariosis
Treatment
Primary treatment (one drug)
Amphotericin B
Deoxycholate 198 (51%)
Lipid/liposomal 45 (11.6%)
Voriconazole 42 (10.8)
Flucytosine 30 (7.7%)
Itraconazole 26 (6.7%)
Fluconazole 25 (6.4%)
Ketoconazole 19 (4.9%)
Rifampicin 13 (3.4)
Posaconazole 3 (0.77%)
Terbinaﬁne —
Natamycin 2 (0.5%)
Surgery 80 (20.6%)
G-CSF 25 (6.4%)
G-Transfusion 13 (3.4%)
No therapy 7 (1.8%)
Combinations (two drugs)
Amphotericin B/voriconazole 24 (6%)
Amphotericin B/5-ﬂucytosine 20 (5%)
Amphotericin B/ketoconazole 4 (1%)
Amphotericin B/ﬂuconazole 4 (1%)
Amphotericin B/posaconazole 2 (0.5%)
Amphotericin B/itraconazole 2 (0.5%)
Amphotericin B/caspofungin 1 (0.26%)
Voriconazole/caspofungin 2 (0.5%)
Voriconazole/anidulafungin 1 (0.26%)
Voriconazole/terbinaﬁne 1 (0.26%)
Ketoconazole/terbinaﬁne 1 (0.26%)
Ketoconazole/rifampicin 1 (0.26%)
Itraconazole/terbinaﬁne 2 (0.5%)
Itraconazole/terbinaﬁne 1 (0.26%)
Combinations (three drugs)
Amphotericin B/ﬂucytosine/rifampicin 2 (0.5%)
Amphotericin B/itraconazole/rifampicin 2 (0.5%)
Amphotericin B/ﬂucytosine/ketoconazole 2 (0.5%)
Amphotericin B/ﬂuconazole/voriconazole 2 (0.5%)
Amphotericin B/ﬂuconazole/itraconazole 1 (0.26%)
Amphotericin B/itraconazole/voriconazole 1 (0.26%)
Amphotericin B/ﬂucytosine/itraconazole 1 (0.26%)
Amphotericin B/ﬂuconazole/rifampicin 1 (0.26%)
Amphotericin B/voriconazole/micafungin 1 (0.26%)
Amphotericin B/voriconazole/terbinaﬁne 1 (0.26%)
Abbreviation: granulocyte–colony-stimulating factor, G-CSF.
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resolution. Almost all of the strains of known species in all complexes
of Fusarium formed independent clades in each tree. A concatenated
tree (Figure 1), including all major human–pathogenic complexes of
Fusarium, was based on 146 selected sequences. The lengths of the
generated sequence data were 795 and 507 bp for RPB2 and TEF1,
respectively. Of the 1302 nucleotides sequenced, 720 (55.1%) were
constant, 551 (42.2%) were parsimony informative and 576 (44.1%)
were variably and parsimony non-informative using MEGA v. 6.2.22
The combined tree was subdivided into several species complexes with
high bootstrap values (Figure 1). Seven clades represented human
opportunists within the F. solani species complex. Thirteen groups
represented opportunistic species in the F. fujikuroi species complex
with smaller human-associated clusters in the FOSC and to a lesser
extent in the F. chlamydosporum, F. polyphialidicum (syn. F. concolor),
F. dimerum and F. incarnatum species complexes. Strains CBS 454.97,
CBS 483.94 and CBS 119850 were identiﬁed morphologically as
F. napiforme but formed a separate cluster that was different from
the three strains including the type strain of F. napiforme (Figure 1).
The AFLP proﬁles contained ~ 50− 60 fragments in the range of
40− 400 bp. The AFLP dendrogram comprised seven main clusters at
the species complex level and additional subgroups within the main
species clusters revealed genetic diversity within each species complex
(Figure 2). However, the proﬁles did not signiﬁcantly vary between the
F. solani species complexes, such as F. falciforme, F. keratoplasticum,
F. lichenicola F. petroliphilum and F. pseudensiforme, whereas there was
signiﬁcant AFLP variation between isolates within the F. fujikuroi
species complex with separate proﬁles for each species and
within other species complexes of F. chlamydosporum, F. concolor,
F. dimerum, F. incarnatum-equiseti and F. oxysporum.
When comparing the AFLP clusters with the distribution of DNA
sequence lineages, the groups were largely concordant. Groups 1− 7
matched with previous identiﬁcations using RPB2 and TEF1
sequences. The Fusarium concolor species complex had one clinical
subgroup, the F. dimerum species complex had two and the Fusarium
fujikuroi species complex consisted of 16 clinical subgroups (15 named
subgroups and 1 unnamed molecular lineage). The FIESC had a single
clinical group, the FOSC was divided into two subgroups and the
F. solani species complex comprised six named and one unnamed
subgroup. The AFLP clusters and subclusters were almost identical to
the sequencing identiﬁcations except for few strains within the
Figure 1 A phylogenetic tree resulting from the RAxML analysis for the RPB2 and TEF1 genes. The total alignment length is 1302 bp. A maximum-
likelihood analysis was performed using RAxML with non-parametric bootstrapping using 1000 replicates. The numbers above the branches are bootstrap
support values ≥0.70. The outgroup was the epitype (ET) strain of F. dimerum CBS 108944.
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Figure 2 Clustering of the ampliﬁed fragment length polymorphism banding pattern of Fusarium spp. combined with a sequence analysis of RPB2 and
TEF1 constructed by Bionumerics v7.5 (Applied Maths). The dendrogram was generated using the Unweighted Pair Group Method with Arithmetic Mean
algorithm.
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F. solani species complex (Figure 2). The AFLP clusters were based on
sequencing and the AFLP data generated from combinations of both
dendrograms. In this study, similar clinical presentations of fusariosis
were observed among the different AFLP species/genotypes, and there
seems to be no relation between species and clinical presentation.
DISCUSSION
The molecular epidemiology of Fusarium was investigated based on
the genetic data generated for the RPB2 and TEF1 sequence analysis
supplemented with the AFLP ﬁngerprint data. The current study
provides information on the locality, sources, species and geographic
distribution in countries in which these fungi are common such as
Brazil, China, Colombia, India, Mexico and the USA. One hundred
and thirty Fusarium isolates, including eight type strains deposited at
the CBS-KNAW collection, were included. Overall, there was a good
correlation between sequence analysis and AFLP genotypes. To analyze
the genetic relationships among the AFLP and sequencing genotypes,
we used phylogenetic algorithms, which are commonly used to detect
evidence of population subdivision and differentiation.26
The second largest subunit of RNA polymerase (RPB2) and
TEF1 showed high resolution with high species-level resolution,
distinguishing 29 Fusarium species including the most common
clinically important Fusarium species F. falciforme, F. keratoplasticum,
F. oxysporum, F. petroliphilum, F. proliferatum and F. verticillioides.
Furthermore, these two loci were able to distinguish between other
rare Fusarium species that cause a variety of infections (Table 1).
Although human opportunists were highlighted in many studies
focusing on speciﬁc regions of the world and speciﬁc types of
infections,10–13,27–34 the 127 Fusarium strains from the current study
were collected from 26 countries in six continents and included
clinical and environmental strains and isolates from cold blooded
animals. Of these, Australia, Brazil, India, Mexico and the USA were
among the top 10 countries with the highest Fusarium infections based
on clinical isolates in the CBS collection. Not surprisingly, 75 of the
127 patients from this study acquired their infection in one of these
countries.
Previously, the majority of the clinically relevant Fusarium species
were classiﬁed as two species complexes that in the past were referred
to as a single species, F. oxysporum and F. solani.35 Approximately 80%
of human infections are caused by members of both species
complexes,36 but a signiﬁcant share of infections is caused by the
following novel species complex members: F. dimerum, F. fujikuroi
and F. incarnatum-equiseti. Within the F. solani complex, there are six
recognized species and one unnamed lineage (FSSC6) clinically
involved in fusariosis (Figure 1). Of these species, F. falciforme
(n= 14/127 cases; 11%) was the dominant species in our study and
mainly isolated from keratitis cases in Brazil, India and Mexico.
Recently, Hassan et al.13 showed that the majority of keratitis cases
(n= 46/65 cases; 70.7%) were F. falciforme. This species is emerging as
one of the most virulent Fusarium species associated with fusariosis
and keratitis.15,36,37
In the 2005–2006 mycotic keratitis outbreaks in Southeast Asia and
North America that were associated with a contact lens cleaning
solution, F. petroliphilum and F. keratoplasticum were the most
common species,36 which is consistent with the current study. The
AFLP genotypic variability was higher in the environmental species
than in the clinical species. A potential explanation is that not all
environmental genotypes are sufﬁciently adapted to the host tissue and
are not selected or perhaps a sampling effect is involved. Zhang et al.35
studied the F. solani species complex, speciﬁcally those species that
cause infections in humans and plants, and concluded that clinical
isolates often shared multi-locus haplotypes with isolates from
different environmental sources, including hospital locations. An
increase of fusariosis among immunosuppressed patients was noted
in the bone marrow transplant unit and among patients with
superﬁcial infections in a hospital in Rio de Janeiro, Brazil.38 These
authors concluded that this increase might be due to airborne conidia
circulating in this geographical region. Short et al.36 concluded that
there is no evidence that clinical isolates differ from those collected
from other sources.
The large diversity of the FOSC is not completely resolved, and it is
not yet known whether the species have one or several phylogenetic
origins or whether a single species or a species complex is concerned.
From a traditional taxonomic point of view, F. oxysporum isolates are
differentiated from each other based on the pathogenicity as formae
speciales, but this has been shown to be an unreliable approach.8 In
addition, the species delimitation was for the FOSC, and at least 26
sequence types within the complex were involved in human
infections.39 Our FOSC clinical isolates were distributed throughout
the complex, although some clustering was found in the clade marked
‘sequence type 33’, which is based on TEF1 alone, and this sequence
type is considered the most common clade that contains clinical
F. oxysporum strains. The remaining species complexes of F. chlamy-
dosporum, F. concolor, F. dimerum and F. incarnatum-equiseti form
separate clusters in the highly resolved sequence-based maximum
likelihood tree (Figure 1).
The FIESC compromises 28 phylogenetically distinct lineages,34 and
only 2 are named and mainly involved in human infections
(F. incarnatum and F. equiseti).40 Although several members of the
FIESC were included in the CDC Fusarium keratitis outbreak
investigations, these species have not yet been observed to occur in
epidemics or cause outbreaks. Concerning geography, 51 clinical
isolates were recovered from the United States, and this revealed that
phylogenetically diverse human opportunists are well represented in
North America.40 In our study, three clinical F. equiseti strains
originated from Mexico, and this might suggest that species of this
complex are common in this region. The virulence of members of the
FIESC has been ascribed to their production of type A and B
trichothecene mycotoxins.39
F. dimerum and F. delphinoides belong to the F. dimerum species
complex, and both were isolated from superﬁcial and disseminated
infections.15 In our data set, a supported clade of FDSC matching with
the AFLP data mainly contained strains from India, and this might
suggest a regional prevalence. F. chlamydosporum was reported in
disseminated infections in patients with aplastic anemia and lympho-
cytic lymphoma from the United States41,42 CBS 111770 (F. concolor)
is the only clinical strain in the F. concolor species complex, and it was
reported in a keratitis case from Spain.43
By comparing AFLP and MLST data, F. falciforme and
F. keratoplasticum appear to be widely distributed, at least in Mexico,
North America, Europe and India, with dominancy in superﬁcial
infections, including keratitis and onychomycosis. F. petroliphilum is
the second most diverse species and is also frequently involved in
disseminated infections. F. solani sensu stricto, ‘5’, which was recently
described as Fusisporium (Fusarium) solani (FSSC5),7 contains strains
such as CBS 135559, CBS 135564 and CBS 135565, which originate
from Mexico, and shows signiﬁcant occurrence in keratitis cases. This
species was also recently reported in Asia (India and Qatar).13,16 Given
the large distances of identical strains occurring in many different
countries, airborne distribution seems likely. However, the presence of
F. incarnatum, F. equiseti and F. chlamydosporum in clinical samples
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from various infections in North America remains puzzling but can
perhaps be explained by sampling effects.
As previously noted,44 the F. fujikuroi complex contains the highest
number of species. In our study, 15 supported clades were recognized
in all of the molecular analyses (Figures 1 and 2). Nearly all of the
clades have various geographic distributions. Within the F. fujikuroi
species complex, F. proliferatum and F. verticillioides were the
dominant clinically relevant species, having a global distribution and
dominating in disseminated infections. F. sacchari is the second most
prevalent species and was often isolated from keratitis restricted to
India. Although F. nygamai and F. napiforme are the most multidrug-
resistant species within the F. fujikuroi complex,45 their presence in
human infections is rare. F. acutatum was reported from nail
infections in four cases in Qatar, showed a low degree of variability
and has been suggested to be clonal.16 These results emphasize that
F. acutatum is an emerging human opportunist, which thus far was
only detected in Asia. Sequence analysis of RPB2 and TEF1, and AFLP
showed that the strains CBS 119850, CBS 483.94 and CBS 454.97 were
nested within the F. fujikuroi complex and close to F. nygamai and
F. andiyazi, forming a well-supported monophyletic branch suggestive
of a novel species.
Deep fusariosis is rare in healthy individuals; a single brain infection
has been reported.46 Local infections may occur after a direct
inoculation or tissue breakdown by trauma or the entrance of foreign
bodies. The treatment of superﬁcial infections is usually successful and
requires surgery, the removal of the foreign body and antifungal
therapy. The most important risk factors for severe fusariosis are
prolonged neutropenia and T-cell immunodeﬁciency in patients
suffering from a hematologic malignancy. Fusarium infections in the
majority of these cases were due to neutropenia. Furthermore, in solid
organ transplant recipients and cancer patients with neutropenia,
infections due to Fusarium spp. increased and led to disseminated
infection. Patients develop painful skin lesions, which vary from
papules to nodules with or without central necrosis.47 In the majority
of disseminated infections, secondary skin lesions led to a diagnosis in
450% of the patients and preceded fungemia by ~ 5 days.48 In
contrast to aspergillosis, fusariosis frequently shows positive blood
cultures because Fusarium conidia are hydrophilic and allow
dissemination.47 Comparing fusariosis with mucormycosis,49 solid
tumors and diabetes do not seem to be important risk factors. Only
17 (4.8%) cases were found in patients with solid tumors, and seven
infections were reported in patients with diabetes mellitus. No
underlying conditions were observed in 20 (5%) of the cases.
Fusarium treatment depends on the site of infection. Surgery with
antifungals was used in 80 cases (20.6%). Disseminated fusariosis in
immunocompromised patients is usually treated with amphotericin B
and voriconazole as the ﬁrst-line therapy, which is suggested by recent
guidelines.50 In our literature review, most antifungal therapy was
amphotericin B deoxycholate, followed by liposomal amphotericin B
and voriconazole. The most commonly used combination is ampho-
tericin B/voriconazole followed by amphotericin B/5-ﬂucytosine.
Triple combinations were used in 14 cases with different antifungals.
The major ﬁndings of the present study include the following:
(i) human-associated fusaria were nested within seven species complexes
(that is, F. chlamydosporum, F. concolor, F. dimerum, F. fujikuroi,
F. incarnatum-equiseti, F. oxysporum and F. solani), (ii) the three most
common species presented in both the clinical and environmental
groups are F. falciforme and F. keratoplasticum (members of F. solani
species complex) followed by F. oxysporum (FOSC), (iii) most of the
reported Fusarium species in this study were shared among the
patients and the environment, and this might be due to the
colonization of some patients with Fusarium isolates from the
environment; hence, there is genetic similarity between the clinical
and environmental isolates of the same Fusarium species, and (iv) the
species distributions show some evidence of geographical clustering
among some of the species studied, although the present study is
limited by an over-representation of isolates from Mexico and India.
ACKNOWLEDGEMENTS
This study was partially funded by the Ministry of Health, Oman (Formal
Agreement NO 28/2014). Abdullah MS Al-Hatmi received a PhD scholarship
from the Ministry of Health, Oman.
1 Al-Hatmi AM, Meis JF, de Hoog GS. Fusarium: molecular diversity and intrinsic drug
resistance. PLoS Pathog 2016; 12: e1005464.
2 Nucci M, Varon AG, Garnica M et al. Increased incidence of invasive fusariosis with
cutaneous portal of entry, Brazil. Emerg Infect Dis 2013; 19: 1567–1572.
3 Mukherjee PK, Chandra J, Yu C et al. Characterization of Fusarium keratitis outbreak
isolates: contribution of bioﬁlms to antimicrobial resistance and pathogenesis. Invest
Ophthalmol Vis Sci 2012; 53: 4450–4457.
4 Short DPG, O’Donnell K, Zhang N et al. Widespread occurrence of diverse pathogenic
types of the fungus Fusarium in bathroom plumbing drains. J Clin Microbiol 2011; 49:
4264–4272.
5 O’Donnell K, Sutton DA, Fothergill A et al. Molecular phylogenetic diversity, multilocus
haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani
species complex. J Clin Microbiol 2008; 4: 2477–2490.
6 Al-Hatmi AMS, Meletiadis J, Curfs-Breuker I et al. In vitro combinations of natamycin
with voriconazole, itraconazole and micafungin against clinical Fusarium isolates
causing keratitis. J Antimicrob Chemother 2016; 71: 953–955.
7 Schroers H-J, Samuels GJ, Zhang N et al. Epitypiﬁcation of Fusisporium (Fusarium)
solani and its assignment to a common phylogenetic species in the Fusarium solani
species complex. Mycologia 2016; 108: 806–819.
8 Garnica M, Nucci M. Epidemiology of fusariosis. Curr Fungal Infect Rep 2013; 7:
301–305.
9 O’Donnell K, Sutton DA, Rinaldi MG et al. Genetic diversity of human pathogenic
members of the Fusarium oxysporum complex inferred from multilocus DNA sequence
data and ampliﬁed fragment length polymorphism analyses: evidence for the recent
dispersion of a geographically widespread clonal lineage and nosocomial origin. J Clin
Microbiol 2004; 42: 5109–5120.
10 Nucci M, Garnica M, Gloria AB et al. Invasive fungal diseases in haematopoietic cell
transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia
in Brazil. Clin Microbiol Infect 2013; 19: 745–751.
11 Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and
immunocompromised hosts: implications for diagnosis and management. Clin Infect
Dis 2002; 35: 909–920.
12 Horn DL, Freifeld AG, Schuster MG et al. Treatment and outcomes of invasive
fusariosis: review of 65 cases from the PATH Alliance registry. Mycoses 2014; 57:
652–658.
13 Hassan AS, Al-Hatmi AMS, Shobana CS et al. Antifungal susceptibility and phylogeny of
opportunistic members of Fusarium species causing human keratomycosis in India.
Med Mycol 2016; 54: 287–294.
14 Daylan Cilo B, Al-Hatmi AM, Seyedmousavi S et al. Emergence of fusariosis in a
university hospital in Turkey during a 20-year period. Eur J Clin Microbiol Infect Dis
2015; 34: 1683–1691.
15 Guevara-Suarez M, Cano-Lira JF, de Garcia MCC et al. Genotyping of Fusarium isolates
from onychomycosis in Colomobia: detection of two new species within the Fusarium
solani species complex and in vitro antifungal susceptibility testing. Mycopathologia
2016; 181: 165–174.
16 Salah H, Al-Hatmi AMS, Theelen B et al. Phylogenetic diversity of human pathogenic
Fusarium and emergence of uncommon virulent species. J Infect 2015; 71: 658–666.
17 Nucci M, Marr KA, Vehreschild MJ et al. Improvement in the outcome of invasive
fusariosis in the last decade. Clin Microbiol Infect 2014; 20: 580–585.
18 Muhammed M, Anagnostou T, Desalermos A et al. Fusarium infection: report of 26
cases and review of 97 cases from the literature. Medicine 2013; 92: 305–316.
19 Reeb V, Lutzoni F, Roux C. Contribution of RPB2 to multilocus phylogenetic studies of
the euascomycetes (Pezizomycotina, Fungi) with special emphasis on the lichen-
forming Acarosporaceae and evolution of polyspory. Mol Phylogenet Evol 2004; 32:
1036–1060.
20 O'Donnell K, Sutton DA, Rinaldi MG et al. Internet-accessible DNA sequence database
for identifying fusaria from human and animal infections. J Clin Microbiol 2010; 48:
3708–3718.
21 Geiser DM, Jimenez-Gasco MD, Kang SC et al. FUSARIUM-ID v. 1.0: a DNA sequence
database for identifying Fusarium. Eur J Plant Pathol 2004; 110: 473–479.
22 Tamura K, Stecher G, Peterson D et al. MEGA6: Molecular Evolutionary Genetics
Analysis version 6.0. Mol Biol Evol 2013; 30: 2725–2729.
23 Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with
thousands of taxa and mixed models. Bioinformatics 2006; 22: 2688–2690.
Molecular epidemiology of human fusariosis
AMS Al-Hatmi et al
10
Emerging Microbes & Infections
24 Stamatakis A, Hoover P, Rougemont J. A rapid bootstrap algorithm for the RAxML Web
servers. Syst Biol 2008; 57: 758–771.
25 Al-Hatmi AMS, Mirabolfathy M, Hagen F et al. DNA barcoding, MALDI-TOF and AFLP
data support Fusarium ﬁcicrescens as a distinct species within the F. fujikuroi species
complex. Fungal Biol 2016; 120: 265–278.
26 Al-Hatmi AMS, Van Den Ende AH, Stielow JB et al. Two novel DNA barcodes for species
recognition of opportunistic pathogens in Fusarium. Fungal Biol 2015; 120: 231–245.
27 Migheli Q, Balmas V, Harak H et al. Molecular phylogenetic diversity of dermatologic
and other human pathogenic fusarial isolates from hospitals in northern and
central Italy. J Clin Microbiol 2010; 48: 1076–1084.
28 Ninet B, Jan I, Bontems O et al. Molecular identiﬁcation of Fusarium species in
onychomycoses. Dermatology 2005; 210: 21–25.
29 López NC, Casas C, Sopo L et al. Fusarium species detected in onychomycosis in
Colombia. Mycoses 2008; 52: 350–356.
30 van Diepeningen AD, Feng P, Ahmed S et al. Spectrum of Fusarium infections in
tropical dermatology evidenced by multilocus sequencing typing diagnostics. Mycoses
2015; 58: 48–57.
31 Homa M, Shobana CS, Singh YR et al. Fusarium keratitis in South India: causative
agents, their antifungal susceptibilities and a rapid identiﬁcation method for the
Fusarium solani species complex. Mycoses 2013; 56: 501–511.
32 Vanzzini Zago V, Manzano-Gayosso P, Hernandez-Hernandez F et al. Mycotic keratitis in
an eye care hospital in Mexico City. Rev Iberoam Micol 2010; 27: 57–61.
33 Lortholary O, Obenga G, Biswas P et al. International retrospective analysis of 73 cases
of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010;
54: 4446–4450.
34 O’Donnell K, Sutton DA, Rinaldi MG et al. Novel multilocus sequence typing scheme
reveals high genetic diversity of human pathogenic members of the Fusarium
incarnatum-F. equiseti and F. chlamydosporum species complexes within the
United States. J Clin Microbiol 2009; 47: 3851–3861.
35 Zhang N, O’Donnell K, Sutton DA et al. Members of the Fusarium solani species
complex that cause infection in both humans and plants are common in the
environment. J Clin Microbiol 2006; 44: 2186–2190.
36 Short DPG, O’Donnell K, Geiser DM. Clonality recombination, and hybridization in the
plumbing-inhabiting human pathogen Fusarium keratoplasticum inferred from multi-
locus sequence typing. BMC Evol Biol 2014; 14: 91.
37 Oechsler RA, Yamanaka TM, Bispo PJ et al. Fusarium keratitis in Brazil: genotyping,
in vitro susceptibilities, and clinical outcomes. Clin Ophthalmol 2013; 7: 1693–1701.
38 Scheel C, Hurst S, Barreiros G et al. Molecular analyses of Fusarium isolates recovered
from a cluster of invasive mold infections in a Brazilian hospital. BMC Infect Dis 2013;
13: 49.
39 O’Donnell K, Gueidan C, Sink S et al. A two-locus DNA sequence database for typing
plant and human pathogens within the Fusarium oxysporum species complex. Fungal
Genet Biol 2009; 46: 936–948.
40 Guarro J. Fusariosis, a complex infection caused by a high diversity of fungal species
refractory to treatment. Eur J Clin Microbiol Infect Dis 2013; 32: 1491–1500.
41 Kiehn TE, Nelson PE, Bernard EM et al. Catheter-associated fungemia caused by
Fusarium chlamydosporum in a patient with lymphocytic lymphoma. J Clin Microbiol
1985; 21: 501–504.
42 Segal BH, Walsh TJ, Liu JM et al. Invasive infection with Fusarium chlamydosporum in
a patient with aplastic anemia. J Clin Microbiol 1998; 36: 1772–1776.
43 Guarro J, Rubio C, Gené J et al. Case of keratitis caused by an uncommon Fusarium
species. J Clin Microbiol 2003; 41: 5823–5826.
44 Al-Hatmi AM, Normand AC, van Diepeningen AD et al. Rapid species-level identiﬁcation
of opportunists in the Fusarium fujikuroi species complex using MALDI-TOF mass
spectrometry. Future Microbiol 2015; 10: 1939–1952.
45 Al-Hatmi AMS, van Diepeningen A, Curfs-Breuker I et al. Speciﬁc antifungal suscept-
ibility proﬁles of opportunists in the Fusarium fujikuroi complex. J Antimicrob
Chemother 2015; 70: 1068–1071.
46 Garcia RR, Min Z, Narasimhan S et al. Fusarium brain abscess: case report and
literature review. Mycoses 2015; 58: 22–26.
47 Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin
Microbiol Rev 2007; 20: 697–704.
48 Dignani MC, Anaissie EJ. Human fusariosis. Clin Microbiol Infect 2004; 10: 67–75.
49 Rombaux P, Eloy P, Bertrand B et al. Lethal disseminated Fusarium infection with sinus
involvement in the immunocompromised host: case report and review of the literature.
Rhinology 1996; 34: 237–241.
50 Tortorano AM, Richardson M, Roilides E et al. ESCMID and ECMM joint guidelines on
diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp.
and others. Clin Microbiol Infect 2014; 20(Suppl 3): 27–46.
This work is licensed under a Creative Commons Attribution 4.0 Inter-
national License. The images or other third party material in this article
are included in the article’s Creative Commons license, unless indicated otherwise in the
credit line; if the material is not included under the Creative Commons license, users will
need to obtain permission from the license holder to reproduce the material. To view a
copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2016
Supplementary Information for this article can be found on the Emerging Microbes & Infections website (http://www.nature.com/emi)
Molecular epidemiology of human fusariosis
AMS Al-Hatmi et al
11
Emerging Microbes & Infections
